Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement)~* CD20\^+ B-cell lymphoma or CD20\^- B-cell and T-cell lymphoma allowed~* B-cell NHL including the following:~  * Stage III follicular lymphoma~ * Stage III follicular lymphoma and diffuse B-cell lymphoma~ * Lymphoblastic precursor B-cell lymphoma~ * Diffuse large cell B-cell lymphoma~    * Centroblastic~   * Immunoblastic~   * Plasmablastic~   * Anaplastic large cell~   * T-cell-rich B-cell lymphoma~   * Primary effusion lymphoma~   * Intravasal B-cell lymphoma~   * Primary mediastinal B-cell lymphoma~ * Mantle zone lymphoma, blastoid~ * Burkitt's lymphoma~ * Burkitt-like lymphoma~ * Aggressive marginal zone lymphoma (monocytoid)~* T-cell NHL including the following:~  * Lymphoblastic precursor T-cell lymphoma~ * Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS)~    * Lennert's lymphoma~   * T-zone lymphoma~ * T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type~ * Anaplastic large cell lymphoma~    * ALK\^+~   * ALK\^-~ * Extranodal NK/T-cell lymphoma, nasal type~ * Intestinal T/NK-cell lymphoma (with or without enteropathy)~    * Hepatosplenic gamma-delta lymphoma~   * Subcutaneous panniculitis-like PTCL~   * Aggressive T/NK PTCL~ * Anaplastic large-cell NHL, NOS~* Bone marrow involvement no more than 25%~* No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract~PATIENT CHARACTERISTICS:~Age~* 61 to 80~Performance status~* ECOG 0-2 OR~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* WBC at least 2,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* No active hepatitis infection~Renal~* Creatinine no greater than 2 times ULN~Cardiovascular~* No Canadian Cardiovascular Society class III or IV angina pectoris~* No New York Heart Association class III or IV cardiac failure~* Ejection fraction at least 50%~* Fractional shortenings at least 25% by echocardiography or nuclear medicine examination~Pulmonary~* FEV1 at least 50%~* Diffusion capacity at least 50%~Other~* No uncontrolled diabetes mellitus~* No known hypersensitivity to any study medications~* No other concurrent malignancy~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy~Surgery~* Not specified~Other~* Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study)~* No other concurrent lymphoma therapy~* No concurrent participation in another treatment study

- Gender: ALL
- Minimum Age: 61 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- S6 (Type: EXPERIMENTAL): 6x CHOP-14
- R6 (Type: EXPERIMENTAL): 6x CHOP-14 + 8x Rituximab
- S8 (Type: EXPERIMENTAL): 8x CHOP-14
- R8 (Type: EXPERIMENTAL): 8x CHOP-14 + 8x Rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete